PDCD1 and cancer: During treatment, effector Tregs decreased and CD8+ T cells in TILs increased, suggesting that a combination of anti-PD-1 mAb with mogamulizumab provides a good antitumor activity with an acceptable safety profile, which could be a potential therapeutic option in cancer immunotherapy [329].